

POLYDEX PHARMACEUTICALS LIMITED

QUARTERLY DISCLOSURE REPORT

APRIL 30, 2019

UNAUDITED

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

INDEX

ITEM I	Name of Issuer	Page	3
ITEM II	Share Structure	Page	3
ITEM III	Consolidated Financial Statements		
	Interim Financial Statements	Page	4-9
	Notes to Interim Financial Statements	Page	10-17
ITEM IV	Management Discussion and Analysis	Page	18-25
ITEM V	Legal Proceedings	Page	26
ITEM VI	Defaults Upon Senior Securities	Page	26
ITEM VII	Other Information	Page	26
ITEM VIII	Exhibits	Page	26
ITEM IX	Certifications	Page	27-28

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM I NAME OF ISSUER

Polydex Pharmaceuticals Limited
421 Comstock Road
Toronto, Ontario, Canada
M1L 2H5
Tel: (416) 755-2231
Fax: (416) 755-0334
Web: www.polydex.com

ITEM II SHARES OUTSTANDING

Preferred Stock – Class A

(i)	Period end date	April 30, 2019
(ii)	Authorized	100,000 shares at \$0.10 each
(iii)	Issued and outstanding	None
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	None

Preferred Stock – Class B

(i)	Period end date	April 30, 2019
(ii)	Authorized	899,400 shares at \$0.0167 each
(iii)	Issued and outstanding	899,400 shares
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	1

Common Stock

(i)	Period end date	April 30, 2019
(ii)	Authorized	10,000,000 shares
(iii)	Issued and outstanding	3,419,478 shares
(iv)	Freely tradable shares (public float)	2,561,166
(v)	Number of shareholders of record	221

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM III INTERIM FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

TABLE OF CONTENTS

Consolidated Balance Sheets April 30, 2019 and January 31, 2019 (Unaudited)	5-6
Consolidated Statements of Operations and Comprehensive Income Three months ended April 30, 2019 and 2018 (Unaudited)	7
Consolidated Statements of Shareholders' Equity Three months ended April 30, 2019 and 2018 (Unaudited)	8
Consolidated Statements of Cash Flows Three months ended April 30, 2019 and 2018 (Unaudited)	9
Notes to Consolidated Financial Statements (Unaudited)	10-17

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
APRIL 30, 2019
UNAUDITED

(Expressed in United States dollars)

	April 30	January 31
	2019	2019
	(Unaudited)	(Unaudited)
Assets		
Current assets:		
Cash	\$937,859	\$1,593,728
Investments available for sale (note 3)	598,854	-
Trade accounts receivable	1,270,405	1,011,959
Inventories		
Finished goods	888,882	513,397
Work in progress	13,878	319,623
Raw materials	<u>281,012</u>	<u>245,761</u>
Prepaid expenses and other current assets	49,134	71,042
Total current assets	4,040,024	3,755,510
Property, plant and equipment, net	3,158,070	3,218,830
Deferred taxes (note 9)	62,500	62,500
Due from estate of former shareholder	20,903	20,903
	\$7,281,497	\$7,057,743

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
APRIL 30, 2019
UNAUDITED

(Expressed in United States dollars)

	April 30 2019	January 31 2019
	(Unaudited)	(Unaudited)
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable	\$571,052	\$370,552
Accrued liabilities	233,428	260,521
Income taxes payable	1,910	1,933
Other loans and advances (note 4)	75,825	75,825
Current portion of long-term debt	63,218	63,898
Current portion of capital lease obligations	3,904	4,141
Current portion of due to shareholder	36,000	36,000
Total current liabilities	985,337	812,870
Long-term debt (note 5a)	185,864	206,538
Capital lease obligations (note 5b)	21,741	5,747
Due to shareholder	308,353	313,712
	515,958	525,997
Total liabilities	1,501,295	1,338,867
Commitments and contingencies (note 6)		
Shareholders' equity:		
Capital stock		
Authorized:		
100,000 Class A preferred shares of \$0.10 each		
899,400 Class B preferred shares of \$0.0167 each		
10,000,000 common shares of \$0.0167 each		
Issued and outstanding:		
899,400 Class B preferred shares (January 31, 2019 - 899,400)	15,010	15,010
3,419,478 common shares (January 31, 2019 - 3,419,478)	56,975	56,975
Contributed surplus	23,807,078	23,807,078
Deficit	(18,344,657)	(18,541,444)
Accumulated other comprehensive income	245,796	381,257
	5,780,202	5,718,876
	\$7,281,497	\$7,057,743

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS
APRIL 30, 2019
UNAUDITED

(Expressed in United States dollars)

	Three Months Ended April 30 2019	Three Months Ended April 30 2018
	(Unaudited)	(Unaudited)
Sales	\$1,221,484	\$1,480,305
Cost of goods sold	896,856	1,239,168
Gross profit	324,628	241,137
Expenses		
General and administrative	143,733	147,096
Interest expense, net	8,685	9,500
Selling and promotion	8,082	22,108
Depreciation	1,557	2,524
Research and development	--	-
Foreign exchange (gain) loss	(31,331)	(44,162)
Interest and other income	(2,885)	(877)
Total expenses	127,841	136,189
Income before income taxes	196,787	104,948
Provision for income taxes (note 9)		
Current	-	-
Deferred	-	-
	-	-
Net income for the period	196,787	104,948
Unrealized gain (loss) on investments available for sale	-	(1,958)
Currency translation adjustment	(135,461)	(252,409)
Comprehensive income for the period	\$61,326	(\$149,419)
Per share information:		
Earnings per common share:		
Basic	0.06	0.03
Diluted	0.06	0.03
Weighted average number of common shares used in computing net income per share for the period:		
Basic	3,419,478	3,419,478
Diluted	3,437,714	3,476,970

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
APRIL 30, 2019
UNAUDITED

(Expressed in United States dollars)

	Three Months Ended April 30 2019	Three Months Ended April 30 2018
	(Unaudited)	(Unaudited)
Preferred Shares:		
Balance, beginning and end of period	\$15,010	\$15,010
Common Shares:		
Balance, beginning and end of period	56,974	56,975
Contributed Surplus:		
Balance, beginning and end of period	23,807,078	\$23,807,078
Deficit:		
Balance, beginning of period	(\$18,541,444)	(\$18,772,389)
Net profit for the period	196,787	104,948
Balance, end of period	(\$18,344,657)	(\$18,667,441)
Accumulated Other Comprehensive Income:		
Balance, beginning of period	\$381,258	\$661,798
Unrealized gain on investments available for sale	-	(1,959)
Currency translation adjustment for the period	(135,461)	(252,409)
Balance, end of period	\$245,797	\$407,430

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
APRIL 30, 2019
UNAUDITED

(Expressed in United States dollars)

	Three Months Ended April 30 2019	Three Months Ended April 30 2018
	(Unaudited)	(Unaudited)
Cash provided by (used in):		
Operating activities:		
Net profit for the period	\$196,787	\$104,948
Add (deduct) items not affecting cash:		
Depreciation and amortization	67,939	73,570
Net change in non-cash working capital balances related to operations	(202,306)	827,988
Cash provided by operating activities	62,420	1,006,506
Investing activities:		
Additions to property, plant and equipment	(78,239)	(43,099)
Increase in investments available for sale	(2,885)	(877)
Proceeds (Acquisition) of investments available for sale	(603,576)	-
Cash used in investing activities	(684,700)	(43,976)
Financing activities:		
Repayment of long-term debt	(15,513)	(15,173)
Proceeds (Repayment) of capital lease obligations, net	(2,054)	(1,392)
Decrease in due to shareholder	(5,358)	(6,260)
Cash used in financing activities	(22,925)	(22,825)
Effect of exchange rate changes	(10,664)	(16,680)
Net increase in cash and cash equivalents	(655,869)	923,025
Cash, beginning of year	1,593,728	632,502
Cash, end of period	\$937,859	\$1,555,527

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM III NOTES TO INTERIM FINANCIAL STATEMENTS

1. Basis of Presentation:

The information contained in the interim consolidated financial statements is condensed from that which would appear in annual consolidated financial statements. The interim consolidated financial statements included herein should be read in conjunction with the unaudited financial statements, and notes thereto, and other financial information contained in the Annual Report for the fiscal year ended January 31, 2019 as found on the Polydex Pharmaceuticals Limited (the “Company”) website, www.polydex.com. The unaudited interim consolidated financial statements as of April 30, 2019 and 2018 include all normal recurring adjustments which management considers necessary for a fair presentation. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the entire fiscal year. The interim consolidated financial statements include the accounts and transactions of the Company and its majority owned subsidiaries in which the Company has equal to or more than a 50% ownership interest and exercises control.

Management has reviewed subsequent events, and there were no material subsequent events since April 30, 2019 that would require recognition or note disclosures in these financial statements.

2. Significant Accounting Policies:

Basis of consolidation

The interim consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company accounts and transactions have been eliminated on consolidation.

Cash and cash equivalents

Cash and cash equivalents include cash and short-term deposits with maturities of less than three months at the date of purchase.

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates relate to the allowance for doubtful accounts, depreciation and amortization rates, and asset impairment charges.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Inventories

Inventories of raw materials are stated at the lower of cost and net realizable value, cost being determined on a first-in, first-out basis. Work-in-process and finished goods are valued at the lower of cost and net realizable value, and include the cost of raw materials, direct labor and fixed and variable overhead expenses.

Investments available for sale

Investments available for sale consist of Canadian Guaranteed Interest Contracts, and are stated at fair market value based on quoted market prices. Interest income is included in other income in the consolidated statement of operations as it is earned. Changes in market values during the holding period are reported as unrealized gain (loss) on investments available for sale and are included in other comprehensive income (loss). Realized gains (losses) are reclassified from accumulated other comprehensive income (loss) on a specific item basis when the security is sold or matured.

Property, plant and equipment and patents and intangible assets

Property, plant and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:

- Buildings 15 to 25 years
- Machinery and equipment 3 to 10 years

Patents and intangible assets are recorded at cost and are amortized on a straight-line basis over their estimated useful lives of ten years. Intangible assets consist of intellectual property, government licenses and government license applications.

Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value.

Costs related to plant refurbishments and equipment upgrades that represent improvements to existing facilities are capitalized. Costs related to repair and maintenance of buildings and equipment are expensed. The Company has no major planned maintenance activity.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Revenue recognition

Revenue results from sales of bulk manufactured products. Revenue is recognized when title and risk of ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer.

Product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping.

Comprehensive income

The Company discloses comprehensive income in their financial statements. In addition to items included in net income, comprehensive income includes items currently charged or credited directly to shareholders' equity, such as foreign currency translation adjustments.

Shipping and handling costs

Shipping and handling costs incurred by the Company for shipment of products to customers are included in cost of goods sold.

Research and development

Research and development costs are expensed as incurred and are stated net of investment tax credits earned.

Foreign currency translation

The functional currency of the Company's Canadian operations has been determined to be the Canadian dollar. All asset and liability accounts of the Company except capital stock have been translated into United States dollars using the current exchange rates at the interim consolidated balance sheet dates. Capital stock is recorded at historical rates. Revenue and expense items are translated using the average exchange rates for the period. The resulting gains and losses have been reported separately as accumulated other comprehensive income within shareholders' equity.

Derivative financial instruments

The Company's Canadian subsidiary from time to time enters into foreign exchange contracts, to manage exposure to currency rate fluctuations related to expected future cash flows. The Company does not engage in speculative trading of derivative financial instruments. The foreign exchange contracts are not designated as hedging instruments, and as a result all foreign exchange contracts are marked to market and the resulting gains and losses are recorded in the consolidated statements of operations in each reporting period. Unrealized gains and losses are included in accrued liabilities in the consolidated balance sheets and in net change in non-cash working capital balances related to operations in the consolidated statements of cash flows. For the quarter ended April 30, 2018 the Company has not entered into any derivative financial instruments.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Stock options

The Company uses the fair value accounting methodology to apply recognition provisions to employee stock options granted, modified or settled. Compensation expense is recorded at the date stock options are granted. The amount of compensation expense is determined by estimating the fair value of the options granted using the Black-Scholes option pricing model.

Income taxes

The Company accounts for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes are provided using the liability method. Under the liability method, deferred income taxes are recognized for all significant temporary differences between the tax and financial statement bases of assets and liabilities.

Effects of changes in enacted tax laws on deferred tax assets and liabilities are reflected as adjustments to tax expense in the period of enactment. Deferred tax assets may be reduced if deemed necessary based on a judgmental assessment of available evidence, by a valuation allowance for the amount of any tax benefits which are more likely, based on current circumstances, not expected to be realized.

Income per common share

Basic earnings per common share is computed using the weighted average number of common shares outstanding of 3,419,478 for the three months ended April 30, 2019 (2018 – 3,399,978). Diluted earnings per common share is computed using the weighted average number of common shares outstanding adjusted for the incremental shares, using the treasury stock method, attributed to outstanding options to purchase common stock. 18,236 incremental shares were used in the calculation of diluted earnings per common share for the period ending April 30, 2019 (2018 – 57,492).

3. Investments Available For Sale:

Investments available for sale, at fair value, consist of the following:

	April 30 2019	January 31 2019
	\$	\$
Guaranteed interest contracts with interest rates varying from 1.9% to 2.55% per annum and varying maturities from February 2020 to February 2027	598,854	--
	598,854	--

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Investments available for sale are stated at fair value, based on quoted market prices. The Company expects that the investments available for sale may be used for working capital for fiscal 2020 and onwards. Accordingly the investments available for sale were classified as part of current assets as at April 30, 2019.

4. Other loans and advances:

Other loans and advances consist of the following:

	April 30 2019	January 31 2019
	\$	\$
Customer advance	75,825	75,825

The advance from a customer is non-interest bearing, unsecured, and repayable on demand.

5. Long term debt obligations:

[a] Bank term loans consist of the following:

	April 30 2019	January 31 2019
	\$	\$
Bank term loan #1 payable in monthly installments of Cdn \$5,594 (U.S. \$4,167) principal and interest at the Canadian bank's fixed rate of 4.98%	83,606	97,159
Bank term loan #2 payable in monthly installments of Cdn \$2,527 (U.S. \$1,883) principal and interest at the Canadian bank's fixed rate of 3.97%	165,476	173,277
	249,082	270,436
Less: current portion	63,218	63,898
	185,864	206,898

Bank term loan #1 was arranged in January 2016 for 60 months at a fixed rate of prime plus 1.50% (2019 and 2018 - 4.20%). On January 29, 2019 the loan was renewed at a fixed rate of 4.98 % per annum maturing January 29, 2021.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Bank term loan #2 was arranged in December 2017 for 120 months at a fixed rate of prime plus 1.50% (2019 and 2018 - 3.97%).

The Company also obtained an operating loan facility of Cdn \$300,000 (USD – \$223,497) for working capital purposes, which was not utilized at January 31, 2019 and April 30, 2019. This Canadian operating facility bears interest at the Canadian bank’s prime lending rate plus 2.15%.

Bank debt and facility are collateralized by a general security agreement over the Company's assets and a collateral mortgage of Cdn \$500,000 (USD – \$372,495) on the Company’s building located in Toronto, Canada.

The Company was in compliance with all covenants as of April 30, 2019.

Interest expense for the quarter on the loans were \$2,781 (2018 - \$4,734)

[a] Principal repayments on the bank loans are as follows:

	\$
2020	63,218
2021	53,697
2022	17,670
2023	18,384
2024	96,113
Thereafter	-
	249,082

[b] Capital lease obligations consist of the following:

	April 30 2019	January 31 2019
	\$	\$
Obligation (Cdn. \$16,737) under a capital lease, repayable in quarterly installments of \$1,260 (U.S. \$745) bearing interest at 9.42% and maturing in 2021	-	13,039

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Obligations (Cdn. \$34,423) under a capital leases, repayable in quarterly installments of \$2,134 (U.S. \$1,590) bearing interest at 10.15% and maturing in 2024	25,645	—
Less current portion	(3,904)	(3,949)
	21,741	9,090

Future minimum annual lease payments on the capital lease obligations including interest are as follows:

	\$
2020	6,362
2021	6,362
2022	6,362
2023	6,362
2024	6,362
Thereafter	1,588
Total minimum lease payments	33,398
Less amount representing imputed interest	7,753
	25,645

Interest expense for the 3 months ended April 30, 2019 for capital lease obligations was \$- (2018 - \$329).

6. Commitments and Contingencies:

In July of 2013, a subsidiary of the Company, Chemdex Inc., renewed its supply agreement with an existing customer and signed an agreement to supply raw materials for an additional product. The agreement is for a period of ten years, renewable for another ten years, and provides the customer with exclusive rights to these raw materials in the United States.

The Company has committed to purchase approximately \$140,000 of partially finished product from a contract manufacturer.

There were no other material commitments or contingencies outstanding as of April 30, 2019.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

7. Stock-based Employee Compensation:

The Company uses the fair value method to account for awards of stock-based employee compensation. No stock-based employee compensation expense was recorded during the period from February 1, 2019 to April 30, 2019, because there were no options granted during this period. Similarly, no stock-based employee compensation expense was recorded during the period from February 1, 2018 to April 30, 2018, because there were no options granted during that period.

8. Provision for Income Taxes

The Company's current income tax provision relates to income taxes owing at its subsidiary Chemdex, Inc.

9. Segmented Information:

Total revenue by significant customer:

	Three Months Ended April 30 2019	Three Months Ended April 30 2018
	\$	\$
Customer A	485,604	-
Customer B	165,900	91,237
Customer C	139,838	-
Customer D	119,838	100,887
Customer E	36,792	124,825
Customer F	34,391	67,350
Customer G	-	304,000
Customer H	-	228,465
	982,363	916,764

Sales by geographic destination:

	Three Months Ended April 30 2019	Three Months Ended April 30 2018
	\$	\$
United States	718,482	522,992
Europe	224,329	712,048
Canada	119,838	100,885
Other	108,810	143,080
Pacific Rim	50,025	1,300
	1,221,484	1,480,305

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM IV MANAGEMENT DISCUSSION AND ANALYSIS

The Company's fiscal year ends on January 31st of each year. In this report, fiscal year 2020 refers to the Company's fiscal year ending January 31, 2020. The following discussion should be read in conjunction with the April 30, 2019 interim consolidated financial statements and notes thereto included elsewhere in this report. Operating results for the three months ended April 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2020. For further information, refer to the Polydex Pharmaceuticals Limited Annual Report on our website, www.polydex.com. The Company's financial statements are prepared in accordance with United States generally accepted accounting principles. All amounts are in United States dollars, unless otherwise denoted.

Overview

The Company is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the manufacture and marketing of biotechnology-based products for the human pharmaceutical market. On May 1, 2017 The Company's Canadian subsidiaries, Dextran Products Limited and Polydex Chemicals Canada Limited were amalgamated into the parent company Polydex Pharmaceuticals Limited.

The manufacture and sale of bulk quantities of dextran and derivative products for sale to large pharmaceutical companies throughout the world is conducted through the Dextran Products division in Canada. Chemdex in the United States provides ferric hydroxide and hydrogenated dextran to Sparhawk pursuant to a definitive supply agreement.

Management Objectives for Fiscal 2020:

We are pleased to see an improvement in the first quarter results now that our powder production equipment was operational for part of the period. No orders were lost due to the downtime. The order book remains strong in the new year with increased orders from existing customers and the potential for interest from new customers.

We have also outsourced a large order to a custom spray drying organization with whom we have an established relationship and management continues to actively pursue bringing our second dryer online.

The Purified Water System is now online and resulting in incremental improvements in product quality. This is all part of our focus on quality, productivity and efficiency and efforts to control utility costs and general costs of production.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 APRIL 30, 2019
 UNAUDITED

Results of Operations

Three months ended April 30, 2019 compared to three months ended April 30, 2018:

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Net Profit	\$196,786	\$104,948	87.5%
Income per Share:			
Basic	\$0.06	\$0.03	
Diluted	\$0.06	\$0.03	

The increase in net profit for the first quarter of fiscal year 2020 is primarily a result of increased gross margins. If not for an increase in the value of the Canadian dollar subsequent to the year end this net profit improvement would have been higher.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Sales	\$1,221,484	\$1,480,305	(17.5)%

Sales decreased for the first quarter of fiscal year 2020 from the comparable period for the first quarter of 2019 as a result of production equipment issues.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Gross profit	\$324,628	\$241,137	34.5%

Percentage of sales	27%	16%
---------------------	-----	-----

The increase in gross profit in the first quarter of fiscal year 2020 was due to a large powdered order completed in the quarter. This was one of our objectives for fiscal 2020 to increase powdered production.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Selling, promotion, general and administrative expenses	\$151,755	\$169,204	(11%)

The decrease during the first quarter of fiscal year 2020 in selling, promotion, general and administrative expenses compared to the comparable period of fiscal 2019 is primarily due to the change in foreign exchange rates in the first quarter of the year compared to the year end rate. There was also a commission paid in fiscal 2019 that won't be paid until the 2nd or 3rd quarter of this year.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Research and development expenditures	\$ ---	\$ --	(0)%

During fiscal year 2010 all of the Company's research into Ushercell was halted, with only some patent expenses being incurred. Since that time further patent fees have been curtailed, with no patent maintenance fees occurring in the first quarter of fiscal 2020 or fiscal 2019.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Depreciation and amortization expense	\$67,939	\$73,570	26%

The decrease in depreciation and amortization resulted from management's change in accounting policy for the estimate of the useful life of the new building. The amortization period for the new building was changed from fifteen to twenty-five years. Depreciation was also impacted by the decreased value of the Canadian dollar.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Interest expense	\$8,685	\$9,500	(9%)

The decrease in interest expense in the first quarter of fiscal year 2020 was due to the decreased value in the Canadian dollar as the company continues to pay down loans.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Foreign exchange (gain) loss	\$(31,331)	\$(44,162)	(29%)

The decrease in the foreign exchange gain for the first quarter of fiscal year 2020 was due to the change in product mix and decrease in sales. The volatility of these exchange rates increase or decrease the value of exchange affected amounts in the Company's Canadian division, Dextran Products, especially U.S. denominated sales.

	Three Months Ended April 30 2019	Three Months Ended April 30 2018	Variance
Interest and other income	\$2,885	\$877	329%

Interest and other income increased compared to the prior year. The company realized a loss on the disposition of investments and the end of the last fiscal year and invested in a series of guaranteed interest rate contracts in the current fiscal year. These contracts provide consistent and steady returns with no risk of capital erosion.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Liquidity and Capital Resources

As of April 30, 2019, the Company had cash and investments of \$1,536,713 compared to cash and investments of \$1,593,728 at January 31, 2019. In the first quarter of fiscal year 2020, the Company generated cash of \$62,420 in its operating activities, compared to \$1,006,506 for the first quarter of fiscal year 2019. The decrease in the generation of cash for operations during the first quarter of fiscal year 2019 is primarily due to the timing of receivables collections and an increase in payables to suppliers for the large powdered order that shipped in the last month of the quarter.

The Company's actual working capital increased to \$3,054,687 from \$2,942,640 as at January 31, 2019 and the working capital ratio increased to 4.62 to 1 as of April 30, 2019 compared to 4.10 to 1 as of January 31, 2019.

As of April 30, 2019, the Company had accounts receivable of \$1,270,405 and inventory of \$1,183,772 compared to \$1,011,959 and \$1,078,781 respectively at January 31, 2019 and \$914,106 and \$841,225 respectively at April 30, 2018. Accounts receivable increased due to the timing of sales and while inventory increased due to a shipment received at the end of April.

Accounts payable increased to \$571,052 at April 30, 2019, compared to \$370,552 at January 31, 2019 and \$437,691 at April 30, 2018. Accounts payable increased due to a shipment of raw materials received at the end of April for drying.

During the first quarter of fiscal year 2020, capital expenditures totaled \$78,239 as compared to \$43,099 in the first quarter of fiscal year 2019. The increase was due to plant equipment upgrades. Additional expenditures on capital equipment are planned for the remainder of fiscal 2020.

The change in accumulated other comprehensive income of the Company is primarily attributable to the currency translation adjustment of Dextran Products. Dextran Products' functional currency is the Canadian dollar. This currency translation adjustment arises from the translation of Dextran Products' financial statements to U.S. dollars.

The company arranged new capital leases for office equipment in the current quarter. The capital lease increase was \$23,578 Canadian dollars. Despite this addition overall long term debt decreased as a result of continued loan repayments.

Changes in the relative values of the Canadian dollar and the United States dollar occur from time to time and may, in certain instances, materially affect the Company's results of operations.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

The Company does not believe that the impact of inflation and changing prices has had a material effect on its operations or financial results at any time in the last three years.

Related Party Transactions

The amount outstanding under the due from shareholder as of April 30, 2019 was \$289,081 as compared to \$285,081 at January 31, 2019, including accrued interest. The Company has taken a cumulative provision of \$519,072 at April 30, 2019 (January 31, 2019 \$514,178) against accrued interest on the loan and the other amounts receivable from the estate as noted below. Obligations with respect to the loan transferred to the estate of Thomas C. Usher upon his death in February 2005.

Thomas C. Usher also owed \$250,000 to a subsidiary of the Company, Novadex International Limited, as of April 30, 2019, pursuant to a non-interest bearing loan with no specific repayment terms. The outstanding amount of this loan has not changed from January 31, 2019. The amounts continue to remain owing from the estate of Thomas C. Usher.

As of April 30, 2019, Thomas C. Usher, now through his estate, had pledged 243,263 common shares of the Company as security for these amounts owing to the Company. These common shares had a market value of \$206,774 at April 30, 2019 based on the closing price of the Company's common shares on the Pink Sheets quotation service on April 30, 2019. The Company intends to continue to hold the pledged assets as collateral until the amounts owing discussed above are repaid.

The Company had a commitment to pay an amount equal to one year's salary, \$110,000, to Thomas C. Usher's estate. The amount owing on this commitment as at April 30, 2019 is \$6,962 (January 31, 2019 – \$6,962).

The Company also has an outstanding loan payable to the estate of Ruth Usher, a former director and the widow of Thomas C. Usher. The amount due from the Company pursuant to this loan decreased to \$344,691 as at April 30, 2019 from \$349,691 at January 31, 2019 due to monthly payments by the Company, less interest charges.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical Accounting Policies

The Company's interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, applied on a consistent basis. The critical accounting policies include the use of estimates of allowance for doubtful accounts, the useful lives of assets and the realizability of deferred tax assets.

Management is required to make estimates and assumptions in preparing the consolidated financial statements that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the periods. The actual results could differ from these estimates. Significant estimates made by management include the calculation of reserves for uncollectible accounts, inventory allowances, useful lives of long-lived assets and the realizability of deferred tax assets.

Revenue Recognition

Revenue results from sales of bulk manufactured products and is recognized when title and risk of ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer. Since returns are rare and generally not accepted, management has not made provision for returns. In addition, product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping.

Allowance for Doubtful Accounts

Accounts receivable is stated net of allowances for doubtful accounts. Allowances for doubtful accounts are determined by each reporting unit on a specific item basis. Management reviews the credit worthiness of individual customers and past payment history to determine the allowance for doubtful accounts. Since the majority of sales at Dextran Products are export, Dextran Products maintains credit insurance through a crown corporation which is supported by the Canadian government, for the majority of its customers' receivables. There has been no allowance for doubtful accounts during the past two fiscal years.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

Long-Lived Assets

Long-lived assets are stated at cost, less accumulated depreciation or amortization computed using the straight-line method based on their estimated useful lives ranging from three to twenty five years. Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. A significant change in estimated useful lives could have a material impact on the results of operations. The Company reviews the recoverability of its long-lived assets, including buildings, equipment and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets as well as other fair value determinations.

Deferred Tax Assets

The Company has recorded a valuation allowance on deferred tax assets where there is uncertainty as to the ultimate realization of the future tax deduction. The Company has incurred capital losses, which are only deductible against capital gains. It is not certain that the Company will realize capital gains in the future to use these Canadian capital loss deductions.

Changes in Accounting Policies

No changes in accounting principles or their application have been implemented in the reporting period that would have a material effect on reported income.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM V LEGAL PROCEEDINGS

Not applicable.

ITEM VI DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM VII OTHER INFORMATION

Not applicable.

ITEM VIII EXHIBITS

Not applicable

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM IX CERTIFICATIONS

I, George G. Usher, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 17, 2019

/s/ George G. Usher

Chairman, President and Chief Executive Officer
Polydex Pharmaceuticals Limited

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
APRIL 30, 2019
UNAUDITED

ITEM IX CERTIFICATIONS (Continued)

I, David P.M. Jamestee, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 17, 2019

/s/ David P.M. Jamestee
Chief Financial Officer
Polydex Pharmaceuticals Limited